Reuters logo
BRIEF-Redhill Biopharma announces successful results with Bekinda
2017年6月14日 / 中午12点28分 / 5 个月前

BRIEF-Redhill Biopharma announces successful results with Bekinda

June 14 (Reuters) - Redhill Biopharma Ltd

* Announces successful phase III top-line results with Bekinda for acute gastroenteritis

* Study successfully met its primary endpoint

* Bekinda 24mg was shown to be effective, safe and well tolerated in patients with acute gastroenteritis and gastritis

* Redhill will continue to analyze guard phase III study top-line data, including secondary endpoints

* Plans to meet with FDA to present data and discuss clinical and regulatory path towards potential marketing approval of bekinda 24mg in U.S. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below